Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Kumar SK, et al. Among authors: faber e jr. Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28. Lancet Oncol. 2020. PMID: 32866432 Free PMC article. Clinical Trial.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. Laubach JP, et al. Among authors: faber ea jr. Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3. Br J Haematol. 2017. PMID: 28466536 Free PMC article.
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
Raje NS, Faber EA Jr, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC. Raje NS, et al. Among authors: faber ea jr. Clin Cancer Res. 2016 Dec 1;22(23):5688-5695. doi: 10.1158/1078-0432.CCR-16-0201. Epub 2016 Jun 10. Clin Cancer Res. 2016. PMID: 27287072 Clinical Trial.
The challenge of cross-trial comparisons using limited data.
Laubach JP, Faber EA Jr, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG. Laubach JP, et al. Among authors: faber ea jr. Haematologica. 2014 Aug;99(8):e145-6. doi: 10.3324/haematol.2013.103135. Haematologica. 2014. PMID: 25082787 Free PMC article. No abstract available.
Multiple myeloma, version 1.2013.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Anderson KC, et al. Among authors: faber ea jr. J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7. doi: 10.6004/jnccn.2013.0004. J Natl Compr Canc Netw. 2013. PMID: 23307977
Peripheral-blood stem cells versus bone marrow from unrelated donors.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Anasetti C, et al. N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517. N Engl J Med. 2012. PMID: 23075175 Free PMC article. Clinical Trial.
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA; NCCN (National Comprehensive Cancer Network). Anderson KC, et al. Among authors: faber ea jr. J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9. doi: 10.6004/jnccn.2012.0128. J Natl Compr Canc Netw. 2012. PMID: 23054875
Multiple myeloma.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F; National Comprehensive Cancer Network. Anderson KC, et al. Among authors: faber ea jr. J Natl Compr Canc Netw. 2011 Oct;9(10):1146-83. doi: 10.6004/jnccn.2011.0095. J Natl Compr Canc Netw. 2011. PMID: 21975914 No abstract available.
11 results